CDP-choline (cytidine-5′-diphosphate choline), also called citicoline, is one of the most frequently pre scribed drugs for cognitive impairment in several European countries and worldwide [1–3].
In clinical practice, a number of different studies have shown that citicoline is effective in Parkinson’s disease, glaucoma, amblyopia, head trauma and cognitive impairment (CI) of diverse etiology, such as in CI following cerebrovascular disease [1-4].
Citicoline is able to inhibit apoptosis associated with cerebral isch emia and several models of neurodegeneration [1–3]. It can also potentiate neuroplasticity and is a natural precursor of phosphatidylcholine, one of the most important structural phospholipids in the neuronal membranes.Furthermore, since it is formed by choline, it works for biosynthesis of acetylcholine [1–3], CDP-choline increases cerebral metabolism, noradrenaline, and dopamine levels in the cen tral nervous system (CNS) [1,4].
Published on: Jul 17, 2017 Pages: 18-19
Rafal Tomasz Pawliczak
Medical University of Lodz, Poland
Open Journal of Asthma
ReGenera R&D International for Aging Intervention & San Babila Clinic, Milano, Italy
Archives of Clinical Gastroenterology
Hon. Pierre Guertin
Laval University, Canada
Global Journal of Obesity, Diabetes and Metabolic Syndrome
CHA University, Republic of Korea
International Journal of Immunotherapy and Cancer Research
Southeastern University, China
Peertechz Journal of Computer Science and Engineering